Travere Therapeutics Non-GAAP EPS of $0.37 in-line, revenue of $129.69M misses by $17.99M
Source: SeekingAlpha
2026-02-19 16:04:15 ET
More on Travere Therapeutics
- Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think
- Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential
- Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Travere Therapeutics Q4 2025 Earnings Preview
- Travere plummets as FDA extends Filspari review for rare kidney disorder
Read the full article on Seeking Alpha
For further details see:
Travere Therapeutics Non-GAAP EPS of $0.37 in-line, revenue of $129.69M misses by $17.99M
Travere Therapeutics Inc Com
NASDAQ: TVTX
TVTX Trading
0.41% G/L:
$27.18 Last:
259,882 Volume:
$27.83 Open:
TVTX Latest News
February 19, 2026 04:01:00 pm
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
TVTX Stock Data
$2,723,537,634
85,723,436
0.56%
88
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
